GLP-1 Drugs: The Evidence Behind the Hype

GLP-1 receptor agonists have become the most talked-about drugs in the world. But separating the clinical evidence from the marketing machine requires a closer look at the data.

What the Studies Actually Show

The SURMOUNT-1 trial showed tirzepatide achieving 20.9% mean weight reduction — genuinely significant. The STEP trials for semaglutide showed 14.9%. For context, bariatric surgery typically achieves 25-30%.

The signal is real. The question is sustainability, side effects, and who the ideal patient actually is.

The Side Effect Profile

Nausea affects roughly 44% of users in clinical trials. Most resolve within 4-8 weeks. Serious adverse events including pancreatitis remain rare (<0.1%) but warrant monitoring in at-risk patients.

The Verdict

GLP-1 agonists are among the most evidence-backed weight management interventions available. They are not a miracle cure, not appropriate for everyone, and almost certainly overprescribed in the current hype cycle — but the underlying science is solid.

Not medical advice. Consult your GP before considering any pharmacological intervention.